Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions

Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions

In Sweden, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 and replaced by the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) or the 13-valent PCV (PCV13) from late 2009. We assessed the impact of PCVs on rates of antibiotic prescribi...

Full description

Bibliographic Details
Main Authors: Mark Edmondson-Jones, Therese Dibbern, Marcus Hultberg, Bengt Anell, Emma Medin, Yang Feng, Carla Talarico
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cost
otitis media
sweden
antibiotics
pneumococcal conjugate vaccines
Online Access:http://dx.doi.org/10.1080/21645515.2021.1942712

Internet

http://dx.doi.org/10.1080/21645515.2021.1942712

Similar Items